VTE risk models in multiple myeloma show low predictive accuracy, pooled AUC below 0.7
Current risk tools for blood clots in multiple myeloma patients do not work well enough for doctors to trust
This systematic review and meta-analysis of 14 studies evaluated VTE risk prediction models in multiple myeloma. Pooled VTE incidence was 7.…
A review of fourteen studies found that existing models fail to accurately predict blood clots in multiple myeloma patients. The tools used …
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Systematic review and meta-analysis of BCMA or GPRC5D bispecific antibodies in relapsed refractory multiple myeloma
New antibodies help some myeloma patients live longer, but infection risks are high
This systematic review and meta-analysis evaluates BCMA- or GPRC5D-directed CD3 bispecific antibodies in 1,900 patients with relapsed or ref…
A review of 1,900 patients found new antibodies helped many with advanced myeloma, yet serious infections and low white blood cell counts re…
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
Narrative review explores natural products targeting proteasome in multiple myeloma
Natural Products May Help Beat Cancer Drug Resistance
This narrative review summarizes literature up to 2025 on natural products that directly target the proteasome or enhance sensitivity to pro…
New natural compounds may help overcome resistance to powerful cancer drugs, offering hope for patients who stop responding to treatment.
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
Meta-analysis compares infection rates of teclistamab in clinical trials and real-world evidence
Teclistamab linked to higher infection rates in some patients
This meta-analysis of 714 patients evaluates the incidence of infections in relapsed/refractory multiple myeloma treated with teclistamab.
New data shows that patients using teclistamab for multiple myeloma may face a significant risk of developing various types of infections.
Case report highlights diagnostic challenges between POEMS syndrome and CIDP
Misdiagnosis of rare nerve disorder highlights need for vigilance
This case report and literature review describes a single patient with POEMS syndrome who was initially misdiagnosed with CIDP.
A single patient's journey from a wrong diagnosis to the truth reveals how easily rare nerve conditions can be missed.
Meta-analysis of CD38-directed CAR-T therapy in relapsed refractory multiple myeloma reports high response rates
New CD38 CAR-T therapy shows high success rates for late-stage multiple myeloma patients
This systematic review and meta-analysis evaluated CD38-directed CAR-T cell therapy in patients with relapsed refractory multiple myeloma.
A new immune therapy targeting CD38 and BCMA offers deep remission for late-stage multiple myeloma patients while managing side effects like…
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
All plasma cell dyscrasias Articles
- VTE risk models in multiple myeloma show low predictive accuracy, pooled AUC below 0.7
- Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
- Systematic review and meta-analysis of BCMA or GPRC5D bispecific antibodies in relapsed refractory multiple myeloma
- FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
- Narrative review explores natural products targeting proteasome in multiple myeloma
- FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
- FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
- Meta-analysis compares infection rates of teclistamab in clinical trials and real-world evidence
- Case report highlights diagnostic challenges between POEMS syndrome and CIDP
- Meta-analysis of CD38-directed CAR-T therapy in relapsed refractory multiple myeloma reports high response rates
- Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
- Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
- Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
- Systematic review of MS proteomics/metabolomics in multiple myeloma cohorts
- Case Report Describes Non-Secretory Multiple Myeloma With Eosinophilia in a 56-Year-Old Man
- Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma
- Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease
- BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients
- Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
- BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients
- Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
- Anti-BCMA CAR T-cell therapy bb21217 with bb007 showed 69.4% response in relapsed multiple myeloma
- Linvoseltamab shows improved outcomes versus real-world standard of care in relapsed/refractory multiple myeloma
- Multiple myeloma diagnosis associated with markedly increased hematologic second primary malignancies in 279,894 patients
- Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma
- Systematic review explores necroptosis as a therapeutic target in multiple myeloma
- CellSearch CMMC assay shows analytical sensitivity for non-invasive MRD monitoring in multiple myeloma
- Real-world study shows lenalidomide-dexamethasone yields 22.9-month PFS in transplant-ineligible myeloma
- Review examines adoptive cellular therapies and immunoproteasome role in relapsed/refractory multiple myeloma
- Phase 1 trial of WVT078 with/without WHG626 shows preliminary activity in relapsed/refractory multiple myeloma
- Bisphosphonates reduce vertebral fracture risk in multiple myeloma, spinal cord compression effect unclear
- FDA Approves Elrexfio for Relapsed or Refractory Multiple Myeloma After Four Prior Lines of Therapy
- SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
- Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial